Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446403 | 0.88 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1CYP1A2 | |
| SCHEMBL1446404 | 0.88 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1CYP1A2 | |
| SCHEMBL13598441 | 0.88 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1CYP1A2 | |
| SCHEMBL4274093 | 0.88 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1CYP1A2 | |
| SCHEMBL14145046 | 0.88 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1CYP1A2 | |
| SCHEMBL393307 | 0.88 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL1861179 | 0.88 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL1861180 | 0.88 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL19550932 | 0.85 | FKBP1A (0.30) | — | |
| SCHEMBL31603219 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016086358-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089722-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CHRM2 613/4885CHRM1 472/4885CHRM3 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.